Medical therapy may be better option after PNL

San Francisco--Second-look nephroscopy following percutaneous nephrolithotomy (PNL) could be supplanted by metabolic evaluation and aggressive medical therapy, said researchers from the Duke University Medical Center. Second-look nephroscopy is currently the gold standard for assessing and achieving stone-free status, but the Duke researchers sought to determine whether this additional procedure was necessary.

Related Videos

Related Content

Advertisement

January 11th 2025

The economics of bladder cancer in the US: Increasing costs and unsustainable patterns

Michael S. Cookson, MD, MMHC

"The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 10th 2025

CREST: Sasanlimab hits primary end point of EFS for NMIBC

Benjamin P. Saylor

Results from CREST will be presented at an upcoming medical conference.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

January 9th 2025

9MW2821/toripalimab awarded breakthrough therapy designation in China for mUC

Hannah Clarke

9MW2821 was previously awarded a breakthrough therapy designation as a monotherapy for locally advanced or metastatic urothelial carcinoma.

January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

Related Content

Advertisement

January 11th 2025

The economics of bladder cancer in the US: Increasing costs and unsustainable patterns

Michael S. Cookson, MD, MMHC

"The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 10th 2025

CREST: Sasanlimab hits primary end point of EFS for NMIBC

Benjamin P. Saylor

Results from CREST will be presented at an upcoming medical conference.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

January 9th 2025

9MW2821/toripalimab awarded breakthrough therapy designation in China for mUC

Hannah Clarke

9MW2821 was previously awarded a breakthrough therapy designation as a monotherapy for locally advanced or metastatic urothelial carcinoma.

January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.